董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jon Congleton | 男 | Independent Director | 62 | 未披露 | 未持股 | 2026-06-01 |
| Richard Rudick | 男 | Independent Director | 75 | 14.95万美元 | 5.03 | 2026-06-01 |
| Daniel Vitt | 男 | Director | 57 | 230.29万美元 | 20.46 | 2026-06-01 |
| Jorg Neermann | 男 | Independent Director | 59 | 15.70万美元 | 5.06 | 2026-06-01 |
| Simona Skerjanec | 女 | Independent Director | 61 | 14.91万美元 | 2.33 | 2026-06-01 |
| Thor Nagel | 男 | Independent Director | 31 | 未披露 | 未持股 | 2026-06-01 |
| Barclay Phillips | 男 | Lead Independent Director | 63 | 17.20万美元 | 3.06 | 2026-06-01 |
| Michael Bonney | 男 | Chair of the Board | 67 | 未披露 | 未持股 | 2026-06-01 |
| Tamar Howson | 女 | Independent Director | 77 | 14.98万美元 | 3.06 | 2026-06-01 |
| Duane Nash | 男 | Director | 55 | 97.99万美元 | 16.23 | 2026-06-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Panzara | 男 | Chief Medical Officer | 59 | 未披露 | 未持股 | 2026-06-01 |
| Jason Tardio | 男 | Chief Operating Officer and President | 49 | 120.35万美元 | 2.84 | 2026-06-01 |
| Hella Kohlhof | 女 | Chief Scientific Officer | 53 | 未披露 | 未持股 | 2026-06-01 |
| Inderpal Singh | 男 | General Counsel | 60 | 未披露 | 未持股 | 2026-06-01 |
| Patrick Walsh | 男 | Chief Business Officer | 43 | 未披露 | 未持股 | 2026-06-01 |
| Glenn Whaley | 男 | Chief Financial Officer | 58 | 106.27万美元 | 6.59 | 2026-06-01 |
| Werner Gladdines | 男 | Chief Development Officer | 47 | 未披露 | 未持股 | 2026-06-01 |
| Erik Lundgren | 男 | Chief Executive Officer | 48 | 未披露 | 未持股 | 2026-06-01 |
董事简历
中英对照 | 中文 | 英文- Jon Congleton
-
Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在Teva Pharmaceutical Industries, Ltd.（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任Teva全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入Teva公司之前，Congleton曾在Sanofi的前身公司担任过十年的各种商业职务。Congleton先生在堪萨斯州立大学获得市场营销学士学位。
Jon Congleton has been a member of Immunic, Inc.'s Board since March 2026. Mr. Congleton has served as President and Chief Executive Officer and as a member of the board of directors of Mineralys Therapeutics, Inc. ("Mineralys") since November 2020. Prior to joining Mineralys, Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries Ltd. (Teva), where for over 18 years, he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University. - Jon Congleton自2020年11月起担任Mineralys Therapeutics，Inc.首席执行官和董事会成员。在加入Mineralys Therapeutics公司之前，Congleton先生于2017年9月至2020年5月担任Impel NeuroPharma公司的首席执行官。在此之前，他曾于2015年1月至2017年2月担任Nivalis Therapeutics，Inc.的首席执行官和董事。Congleton先生曾在Teva Pharmaceutical Industries, Ltd.（Teva）任职超过18年，担任一般管理和全球战略营销职务，包括2013年4月至2014年12月担任Teva全球中枢神经系统疾病高级副总裁，2011年11月至2013年4月担任全球医学集团高级副总裁，以及美国梯瓦神经科学公司总经理。在加入Teva公司之前，Congleton曾在Sanofi的前身公司担任过十年的各种商业职务。Congleton先生在堪萨斯州立大学获得市场营销学士学位。
- Jon Congleton has been a member of Immunic, Inc.'s Board since March 2026. Mr. Congleton has served as President and Chief Executive Officer and as a member of the board of directors of Mineralys Therapeutics, Inc. ("Mineralys") since November 2020. Prior to joining Mineralys, Mr. Congleton was the Chief Executive Officer of Impel NeuroPharma, Inc. from September 2017 to May 2020. Prior to that, he served as the Chief Executive Officer and as a director of Nivalis Therapeutics, Inc. from January 2015 to February 2017. Mr. Congleton was previously at Teva Pharmaceutical Industries Ltd. (Teva), where for over 18 years, he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Global Central Nervous System Disorders from April 2013 to December 2014, Senior Vice President of the Global Medicine Group from November 2011 to April 2013, and General Manager of Teva Neuroscience, Inc. in the United States. Prior to joining Teva, Mr. Congleton spent ten years in a variety of commercial roles with predecessor companies of Sanofi. Mr. Congleton earned a B.S. in marketing from Kansas State University.
- Richard Rudick
-
Richard Rudick，于2023年4月加入董事会。Rudick博士自2023年1月起担任Astoria Biologic的总裁兼首席执行官，该公司是一家开发多发性硬化症新疗法的私营生物技术公司。此前，Rudick博士曾于2014年5月至2020年9月在渤健公司担任发展科学副总裁，该公司是一家生物技术公司，从事发现、开发和提供神经系统和神经退行性疾病的疗法。鲁迪克博士还曾在1987年1月至2014年5月期间担任克利夫兰诊所Mellen中心的职员神经科医生和主任。Rudick博士拥有凯斯西储大学医学院的医学博士学位。
Richard Rudick has served since January 2023 as the President and CEO of Astoria Biologica, a private biotechnology company developing novel therapies for multiple sclerosis. Previously, Dr. Rudick served as the Vice President of Development Science at Biogen, Inc., a biotechnology company which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases, from May 2014 until September 2020. Dr. Rudick also served as a staff neurologist and director of the Mellen Center for the Cleveland Clinic from January 1987 until May 2014. Dr. Rudick holds an M.D. from Case Western Reserve University School of Medicine. - Richard Rudick，于2023年4月加入董事会。Rudick博士自2023年1月起担任Astoria Biologic的总裁兼首席执行官，该公司是一家开发多发性硬化症新疗法的私营生物技术公司。此前，Rudick博士曾于2014年5月至2020年9月在渤健公司担任发展科学副总裁，该公司是一家生物技术公司，从事发现、开发和提供神经系统和神经退行性疾病的疗法。鲁迪克博士还曾在1987年1月至2014年5月期间担任克利夫兰诊所Mellen中心的职员神经科医生和主任。Rudick博士拥有凯斯西储大学医学院的医学博士学位。
- Richard Rudick has served since January 2023 as the President and CEO of Astoria Biologica, a private biotechnology company developing novel therapies for multiple sclerosis. Previously, Dr. Rudick served as the Vice President of Development Science at Biogen, Inc., a biotechnology company which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases, from May 2014 until September 2020. Dr. Rudick also served as a staff neurologist and director of the Mellen Center for the Cleveland Clinic from January 1987 until May 2014. Dr. Rudick holds an M.D. from Case Western Reserve University School of Medicine.
- Daniel Vitt
-
Daniel Vitt是首席执行官和董事会成员，自2019年4月以来一直担任这些职务。2026年5月22日，Daniel Vitt辞去公司首席执行官职务，自2026年6月1日起生效。Vitt博士将继续担任公司董事会成员，并保留科学战略和投资组合推进的责任。2017年1月至2022年，他还担任位于Halle（Saale）的Immunic研究有限公司的董事总经理，该公司是Immunic, Inc.的德国子公司。他于2017年1月从4SC AG加入Immunic,4SC AG是一家公开上市的股票公司，总部位于德国马丁斯里德，他于1997年与他人共同创立了该公司。在4SC，他曾担任首席科学官和首席开发官。此外，2011年12月至2017年11月，维特博士担任德国有限责任公司4SC Discovery GmbH的董事总经理。作为4SC执行董事会成员，他负责4SC集团的所有研发活动，包括四个临床阶段产品。Vitt博士目前担任德国有限责任公司Listrax UG和德国有限责任公司Brauhaus Germering GmbH的董事总经理。兼任澳大利亚有限责任公司Immunic Australia Pty Ltd.董事。维特博士于1989年至1994年在德国锡根和维尔茨堡学习化学，毕业于维尔茨堡大学。博士期间，他专注于小分子疗法的分子设计。1998年获维尔茨堡大学有机化学研究所博士学位。
Daniel Vitt is Chief Executive Officer and a member of the board, positions he has held since April 2019. On May 22, 2026, Daniel Vitt, resigned as the Chief Executive Officer of the Company, effective June 1, 2026. Dr. Vitt will continue to serve as a member of the Company's Board, and retain responsibility for scientific strategy and portfolio advancement. From January 2017 to 2022, he was also managing director of Immunic Research GmbH in Halle (Saale), Immunic, Inc.'s Germany subsidiary. He joined Immunic in January 2017 from 4SC AG, a publicly listed stock company based in Martinsried, Germany, which he co founded in 1997. At 4SC, he served as Chief Scientific Officer and Chief Development Officer. In addition, from December 2011 to November 2017, Dr. Vitt served as managing director of 4SC Discovery GmbH, a German limited liability company. As a member of the executive board of 4SC, he was responsible for all research and development activities at 4SC group including four clinical stage products. Dr. Vitt currently serves as managing director for Listrax UG, a German limited liability company, and Brauhaus Germering GmbH, a German limited liability company. He is also a director of Immunic Australia Pty Ltd., an Australian limited liability company. Dr. Vitt studied chemistry in Siegen and Würzburg, Germany from 1989 to 1994 and graduated from the University of Würzburg. During his doctoral studies, he focused on the molecular design of small molecule therapeutics. In 1998, he received his Ph.D. from the Institute of Organic Chemistry at the University of Würzburg. - Daniel Vitt是首席执行官和董事会成员，自2019年4月以来一直担任这些职务。2026年5月22日，Daniel Vitt辞去公司首席执行官职务，自2026年6月1日起生效。Vitt博士将继续担任公司董事会成员，并保留科学战略和投资组合推进的责任。2017年1月至2022年，他还担任位于Halle（Saale）的Immunic研究有限公司的董事总经理，该公司是Immunic, Inc.的德国子公司。他于2017年1月从4SC AG加入Immunic,4SC AG是一家公开上市的股票公司，总部位于德国马丁斯里德，他于1997年与他人共同创立了该公司。在4SC，他曾担任首席科学官和首席开发官。此外，2011年12月至2017年11月，维特博士担任德国有限责任公司4SC Discovery GmbH的董事总经理。作为4SC执行董事会成员，他负责4SC集团的所有研发活动，包括四个临床阶段产品。Vitt博士目前担任德国有限责任公司Listrax UG和德国有限责任公司Brauhaus Germering GmbH的董事总经理。兼任澳大利亚有限责任公司Immunic Australia Pty Ltd.董事。维特博士于1989年至1994年在德国锡根和维尔茨堡学习化学，毕业于维尔茨堡大学。博士期间，他专注于小分子疗法的分子设计。1998年获维尔茨堡大学有机化学研究所博士学位。
- Daniel Vitt is Chief Executive Officer and a member of the board, positions he has held since April 2019. On May 22, 2026, Daniel Vitt, resigned as the Chief Executive Officer of the Company, effective June 1, 2026. Dr. Vitt will continue to serve as a member of the Company's Board, and retain responsibility for scientific strategy and portfolio advancement. From January 2017 to 2022, he was also managing director of Immunic Research GmbH in Halle (Saale), Immunic, Inc.'s Germany subsidiary. He joined Immunic in January 2017 from 4SC AG, a publicly listed stock company based in Martinsried, Germany, which he co founded in 1997. At 4SC, he served as Chief Scientific Officer and Chief Development Officer. In addition, from December 2011 to November 2017, Dr. Vitt served as managing director of 4SC Discovery GmbH, a German limited liability company. As a member of the executive board of 4SC, he was responsible for all research and development activities at 4SC group including four clinical stage products. Dr. Vitt currently serves as managing director for Listrax UG, a German limited liability company, and Brauhaus Germering GmbH, a German limited liability company. He is also a director of Immunic Australia Pty Ltd., an Australian limited liability company. Dr. Vitt studied chemistry in Siegen and Würzburg, Germany from 1989 to 1994 and graduated from the University of Würzburg. During his doctoral studies, he focused on the molecular design of small molecule therapeutics. In 1998, he received his Ph.D. from the Institute of Organic Chemistry at the University of Würzburg.
- Jorg Neermann
-
J rg Neermann，自2019年4月起担任董事会成员。他最近在2021年5月至2022年9月期间担任私人控股的德国生物技术公司Curexsys GmbH的首席执行官。在此之前至2020年底，Neermann博士曾任职于Life Sciences Partners（“LSP”），并担任LSP Services Deutschland GmbH的董事总经理，该公司为该公司的股东之一LSP V Co peratieve U.A.提供管理服务。他于2007年加入LSP。Neermann博士在LSP的主要关注点和职责是投资非上市证券。在加入LSP之前，Neermann博士是Deutsche Venture Capital的董事总经理，该公司是德意志银行的风险投资和私募股权部门，负责经营该公司的医疗保健投资专营权。此前，他曾任职于德国Atlas Ventures，也曾投资于医疗保健领域。Neermann博士拥有强大的科学背景和实际操作的金融和投资专长，曾在众多欧洲生物技术和生命科学公司的董事会任职。Neermann博士目前是德国生物技术公司Vivoryon N.V.的非执行董事，该公司于2014年在阿姆斯特丹泛欧交易所上市，积极开发针对阿尔茨海默病的新型疾病改善疗法，以及德国私营公司Idea AG。Neermann博士此前是ViCentra B.V.和Eyesense GmbH的监事会成员，任期至2021年1月，Ventaleon GmbH任期至2020年12月，Kuros AG任期至2017年5月。Neermann博士曾就读于德国布朗斯威克工业大学和美国剑桥麻省理工学院生物技术专业，拥有德国布朗斯威克工业大学生物技术硕士学位和博士学位。他还曾就读于德国布朗斯威克工业大学、哈佛商学院经济学专业。
Jorg Neermann has been a member of the Board since April 2019. Since 2023, Dr. Neermann has been a venture partner with Vorwerk Ventures, a private venture capital fund. He most recently served as the CEO of the privately held German biotech company, Curexsys GmbH from May 2021 until September 2022. Prior to this until the end of 2020, Dr. Neermann worked for Life Sciences Partners ("LSP") and was the managing director of LSP Services Deutschland GmbH, which provides management services for LSP V Coperatieve U.A., one of the Company's stockholders. He joined LSP in January 2007 and left the company in early 2021. Dr. Neermann's prime focus and responsibility within LSP was to invest in unlisted securities. Prior to joining LSP, Dr. Neermann was the managing director of Deutsche Venture Capital, a venture capital and private equity division of Deutsche Bank, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany where he also invested in the healthcare sector. Dr. Neermann has a strong scientific background and hands on finance and investment expertise and has served on the boards of numerous European biotech and life science companies. From September 2011 until June 2023, Dr. Neermann served as a non executive director at Vivoryon N.V., a German biotech company that went public on Euronext Amsterdam in 2014, which is active in the development of novel, disease modifying therapeutics against Alzheimer's disease. Currently, Dr. Neermann serves as a non executive director at Idea AG, a private German company. Dr. Neermann was previously a supervisory board member of ViCentra B.V., a Dutch limited liability company, and Eyesense GmbH, a German limited liability company, until January 2021, Ventaleon GmbH, a German limited liability compan, until December 2020, and Kuros AG, a Swiss headquartered company, until May 2017. Dr. Neermann was also a board member of Imcyse S.A., a Belgian limited liability company, until January 2021. Currently, he is owner and managing director of Betula29 GmbH, a German limited liability company. Dr. Neermann studied biotechnology at the Technical University of Brunswick, Germany, and MIT in Cambridge, USA, and holds a Master's degree and a Ph.D. in biotechnology from the Technical University in Brunswick, Germany. He also studied economics at the Technical University in Brunswick, Germany, and Harvard Business School. - J rg Neermann，自2019年4月起担任董事会成员。他最近在2021年5月至2022年9月期间担任私人控股的德国生物技术公司Curexsys GmbH的首席执行官。在此之前至2020年底，Neermann博士曾任职于Life Sciences Partners（“LSP”），并担任LSP Services Deutschland GmbH的董事总经理，该公司为该公司的股东之一LSP V Co peratieve U.A.提供管理服务。他于2007年加入LSP。Neermann博士在LSP的主要关注点和职责是投资非上市证券。在加入LSP之前，Neermann博士是Deutsche Venture Capital的董事总经理，该公司是德意志银行的风险投资和私募股权部门，负责经营该公司的医疗保健投资专营权。此前，他曾任职于德国Atlas Ventures，也曾投资于医疗保健领域。Neermann博士拥有强大的科学背景和实际操作的金融和投资专长，曾在众多欧洲生物技术和生命科学公司的董事会任职。Neermann博士目前是德国生物技术公司Vivoryon N.V.的非执行董事，该公司于2014年在阿姆斯特丹泛欧交易所上市，积极开发针对阿尔茨海默病的新型疾病改善疗法，以及德国私营公司Idea AG。Neermann博士此前是ViCentra B.V.和Eyesense GmbH的监事会成员，任期至2021年1月，Ventaleon GmbH任期至2020年12月，Kuros AG任期至2017年5月。Neermann博士曾就读于德国布朗斯威克工业大学和美国剑桥麻省理工学院生物技术专业，拥有德国布朗斯威克工业大学生物技术硕士学位和博士学位。他还曾就读于德国布朗斯威克工业大学、哈佛商学院经济学专业。
- Jorg Neermann has been a member of the Board since April 2019. Since 2023, Dr. Neermann has been a venture partner with Vorwerk Ventures, a private venture capital fund. He most recently served as the CEO of the privately held German biotech company, Curexsys GmbH from May 2021 until September 2022. Prior to this until the end of 2020, Dr. Neermann worked for Life Sciences Partners ("LSP") and was the managing director of LSP Services Deutschland GmbH, which provides management services for LSP V Coperatieve U.A., one of the Company's stockholders. He joined LSP in January 2007 and left the company in early 2021. Dr. Neermann's prime focus and responsibility within LSP was to invest in unlisted securities. Prior to joining LSP, Dr. Neermann was the managing director of Deutsche Venture Capital, a venture capital and private equity division of Deutsche Bank, where he ran its healthcare investment franchise. Previously, he worked at Atlas Ventures in Germany where he also invested in the healthcare sector. Dr. Neermann has a strong scientific background and hands on finance and investment expertise and has served on the boards of numerous European biotech and life science companies. From September 2011 until June 2023, Dr. Neermann served as a non executive director at Vivoryon N.V., a German biotech company that went public on Euronext Amsterdam in 2014, which is active in the development of novel, disease modifying therapeutics against Alzheimer's disease. Currently, Dr. Neermann serves as a non executive director at Idea AG, a private German company. Dr. Neermann was previously a supervisory board member of ViCentra B.V., a Dutch limited liability company, and Eyesense GmbH, a German limited liability company, until January 2021, Ventaleon GmbH, a German limited liability compan, until December 2020, and Kuros AG, a Swiss headquartered company, until May 2017. Dr. Neermann was also a board member of Imcyse S.A., a Belgian limited liability company, until January 2021. Currently, he is owner and managing director of Betula29 GmbH, a German limited liability company. Dr. Neermann studied biotechnology at the Technical University of Brunswick, Germany, and MIT in Cambridge, USA, and holds a Master's degree and a Ph.D. in biotechnology from the Technical University in Brunswick, Germany. He also studied economics at the Technical University in Brunswick, Germany, and Harvard Business School.
- Simona Skerjanec
-
Simona Skerjanec，曾担任Sarepta医疗美国商业机构的高级副总裁兼总经理，业务包括市场准入、贸易与分销、报销、销售、患者服务和市场营销。2017年至2019年，她在赛诺菲 Genzyme担任副总裁、罕见神经、代谢和内分泌疾病全球治疗领域负责人，在那里她管理着一个1.6B美元的投资组合，拥有五个已上市和三个管道产品，并在多个联盟中担任商业领导。从2011年到2017年，T rns é n女士在Shire的内分泌和罕见疾病组担任推进商业化职务，升任副总裁、美国商业内分泌罕见病销售主管。在她职业生涯的早期，她获得了全球营销方面的经验，并分别在默沙东 KGaA和礼来担任产品专家。T rns é n女士获得瑞典隆德大学国际工商管理理学硕士（理学硕士）学位。
Simona Skerjanec has nearly thirty years of global experience in the pharmaceutical industry overseeing product commercialization and business strategy initiatives. From March 2015 until December 2023, Ms. Skerjanec held several leadership positions at Roche in Switzerland, where she most recently served as Senior Vice President, Global Head of Neuroscience and Rare Diseases. In this role, Ms. Skerjanec led business and global corporate strategy for Roche's portfolio of neurological and rare diseases. Previously, Ms. Skerjanec served as General Manager of Roche in Portugal and served as the Neuroimmunology Franchise Head where she was in charge of certain drug commercialization efforts on behalf of the company. Prior to joining Roche, Ms. Skerjanec was Senior Vice President and Cardiovascular Franchise Head at The Medicines Company where she held various roles in development and commercialization from July 2003 to February 2015. Before her employment at The Medicines Company, Ms. Skerjanec held positions at Eli Lilly, Pfizer, and Johnson & Johnson. Since May 2024, Ms. Skerjanec has served on the board of directors of Avidity Biosciences. Ms. Skerjanec received her M.Pharm from the University of Ljubljana School of Pharmacy and her MBA from Fairleigh Dickinson University. - Simona Skerjanec，曾担任Sarepta医疗美国商业机构的高级副总裁兼总经理，业务包括市场准入、贸易与分销、报销、销售、患者服务和市场营销。2017年至2019年，她在赛诺菲 Genzyme担任副总裁、罕见神经、代谢和内分泌疾病全球治疗领域负责人，在那里她管理着一个1.6B美元的投资组合，拥有五个已上市和三个管道产品，并在多个联盟中担任商业领导。从2011年到2017年，T rns é n女士在Shire的内分泌和罕见疾病组担任推进商业化职务，升任副总裁、美国商业内分泌罕见病销售主管。在她职业生涯的早期，她获得了全球营销方面的经验，并分别在默沙东 KGaA和礼来担任产品专家。T rns é n女士获得瑞典隆德大学国际工商管理理学硕士（理学硕士）学位。
- Simona Skerjanec has nearly thirty years of global experience in the pharmaceutical industry overseeing product commercialization and business strategy initiatives. From March 2015 until December 2023, Ms. Skerjanec held several leadership positions at Roche in Switzerland, where she most recently served as Senior Vice President, Global Head of Neuroscience and Rare Diseases. In this role, Ms. Skerjanec led business and global corporate strategy for Roche's portfolio of neurological and rare diseases. Previously, Ms. Skerjanec served as General Manager of Roche in Portugal and served as the Neuroimmunology Franchise Head where she was in charge of certain drug commercialization efforts on behalf of the company. Prior to joining Roche, Ms. Skerjanec was Senior Vice President and Cardiovascular Franchise Head at The Medicines Company where she held various roles in development and commercialization from July 2003 to February 2015. Before her employment at The Medicines Company, Ms. Skerjanec held positions at Eli Lilly, Pfizer, and Johnson & Johnson. Since May 2024, Ms. Skerjanec has served on the board of directors of Avidity Biosciences. Ms. Skerjanec received her M.Pharm from the University of Ljubljana School of Pharmacy and her MBA from Fairleigh Dickinson University.
- Thor Nagel
-
Thor Nagel自2023年7月起担任BVF的分析师，在那里他进行深入的股票研究，并为整个生命科学领域的投资分析做出贡献。从2021年6月到2023年7月，Nagel先生在Monashee Investment Management LLC担任高级分析师。He previoly在Stifel Financial Corp.任职Nagel先生获得美国圣母大学理学硕士学位和范德比尔特大学化学工程学士学位。
Thor Nagel joined the Board in February 2026. Mr. Nagel has served as an Analyst at BVF, since July 2023, where he conducts in depth equity research and contributes to investment analysis across the life sciences sector. From June 2021 through July 2023, Mr. Nagel was a senior analyst at Monashee Investment Management LLC. He previously held roles with Stifel Financial Corp. Mr. Nagel received his Master of Science from the University of Notre Dame and his Bachelor's degree in Chemical Engineering from Vanderbilt University. - Thor Nagel自2023年7月起担任BVF的分析师，在那里他进行深入的股票研究，并为整个生命科学领域的投资分析做出贡献。从2021年6月到2023年7月，Nagel先生在Monashee Investment Management LLC担任高级分析师。He previoly在Stifel Financial Corp.任职Nagel先生获得美国圣母大学理学硕士学位和范德比尔特大学化学工程学士学位。
- Thor Nagel joined the Board in February 2026. Mr. Nagel has served as an Analyst at BVF, since July 2023, where he conducts in depth equity research and contributes to investment analysis across the life sciences sector. From June 2021 through July 2023, Mr. Nagel was a senior analyst at Monashee Investment Management LLC. He previously held roles with Stifel Financial Corp. Mr. Nagel received his Master of Science from the University of Notre Dame and his Bachelor's degree in Chemical Engineering from Vanderbilt University.
- Barclay Phillips
-
Barclay Phillips，2008年8月以来，他一直担任Micromet, Inc.的高级副总裁兼首席财务官。此前，他曾担任Micromet, Inc.的董事会成员（始于2000年），直到他被任命为Micromet, Inc.的首席财务官。从1999年到2008年8月，他担任Vector Fund Manment公司（风险投资公司）的董事总经理。从1991年到1999年，他曾担任 INVESCO Funds Group的多种职务，包括私募董事、生物技术分析师。从1985年到1990年，他曾担任Paine Webber公司和Shearson Lehman Hutton公司的销售和交易职务。他持有Boulder Colorado大学的经济学学士学位。
Barclay Phillips has been a member of the Board since November 2019. From August 2020 to October 2024, Mr. Phillips was Chief Operating Officer and Chief Financial Officer of Ribometrix, Inc., a discovery stage biotechnology company developing RNA targeted small molecule therapeutics. Since September 2019, Mr. Phillips has been the managing member of Domantle Consulting LLC, a business strategy consulting firm for biotechnology companies. From 2008 to May 2019, Mr. Phillips served as the Chief Financial Officer for three separate Nasdaq listed, development stage biotechnology companies; G1 Therapeutics, Inc. (GTHX), Novavax (NVAX) and Micromet (acquired by Amgen in 2012 for $1.2B). In addition to carrying the CFO role, Mr. Phillips also held the title of SVP Corporate Development at G1 Therapeutics. During his tenure as CFO, Mr. Phillips was responsible for all finance and accounting functions, financing strategy (successfully raising over $1.4B), Wall Street and investor relations, public relations and corporate strategy and corporate development. Prior to his CFO experience, Mr. Phillips had extensive experience in life science venture investing and public market investing, serving for 9 years as the Managing Director of Vector Fund Management, a late stage life sciences venture capital fund with over $250 million in committed capital and approximately 30 venture investments in biotechnology, medical technology and healthcare services companies. In addition, Mr. Phillips was Biotechnology Analyst and Director of Venture Investments for INVESCO Funds group, a no load mutual fund family with a healthcare sector fund franchise totaling over $3.5 billion in assets under management. Mr. Phillips has served on the boards of several public and private companies, including roles as Audit Chair and Chair of the Nominating and Corporate Governance committees. He received a Bachelor of Arts degree in economics from the University of Colorado at Boulder. - Barclay Phillips，2008年8月以来，他一直担任Micromet, Inc.的高级副总裁兼首席财务官。此前，他曾担任Micromet, Inc.的董事会成员（始于2000年），直到他被任命为Micromet, Inc.的首席财务官。从1999年到2008年8月，他担任Vector Fund Manment公司（风险投资公司）的董事总经理。从1991年到1999年，他曾担任 INVESCO Funds Group的多种职务，包括私募董事、生物技术分析师。从1985年到1990年，他曾担任Paine Webber公司和Shearson Lehman Hutton公司的销售和交易职务。他持有Boulder Colorado大学的经济学学士学位。
- Barclay Phillips has been a member of the Board since November 2019. From August 2020 to October 2024, Mr. Phillips was Chief Operating Officer and Chief Financial Officer of Ribometrix, Inc., a discovery stage biotechnology company developing RNA targeted small molecule therapeutics. Since September 2019, Mr. Phillips has been the managing member of Domantle Consulting LLC, a business strategy consulting firm for biotechnology companies. From 2008 to May 2019, Mr. Phillips served as the Chief Financial Officer for three separate Nasdaq listed, development stage biotechnology companies; G1 Therapeutics, Inc. (GTHX), Novavax (NVAX) and Micromet (acquired by Amgen in 2012 for $1.2B). In addition to carrying the CFO role, Mr. Phillips also held the title of SVP Corporate Development at G1 Therapeutics. During his tenure as CFO, Mr. Phillips was responsible for all finance and accounting functions, financing strategy (successfully raising over $1.4B), Wall Street and investor relations, public relations and corporate strategy and corporate development. Prior to his CFO experience, Mr. Phillips had extensive experience in life science venture investing and public market investing, serving for 9 years as the Managing Director of Vector Fund Management, a late stage life sciences venture capital fund with over $250 million in committed capital and approximately 30 venture investments in biotechnology, medical technology and healthcare services companies. In addition, Mr. Phillips was Biotechnology Analyst and Director of Venture Investments for INVESCO Funds group, a no load mutual fund family with a healthcare sector fund franchise totaling over $3.5 billion in assets under management. Mr. Phillips has served on the boards of several public and private companies, including roles as Audit Chair and Chair of the Nominating and Corporate Governance committees. He received a Bachelor of Arts degree in economics from the University of Colorado at Boulder.
- Michael Bonney
-
Michael Bonney自2016年10月起担任Magenta Therapeutics, Inc.董事会成员和主席。Bonney先生自2017年6月起担任Kaleido Biosciences，Inc.的行政总裁及主席。2016年1月至7月，Bonney是医疗保健风险投资公司Third Rock Ventures的合伙人。Bonney先生曾在2003年6月至2014年12月期间担任Cubist Pharmaceuticals，Inc.或Cubist的首席执行官和董事会成员，Cubist是一家生物制药公司，现在是默克制药公司的全资子公司。2002年1月至2003年6月担任Cubist总裁兼首席运营官，Bonney先生是医疗保健专用、公开交易基金Tekla Complex的受托人，此外，Bonney先生目前担任Celgene Corporation、Alnylam Pharmaceuticals Inc.和Sarepta Corporation的董事，Bonney先生曾担任NPS Pharmaceuticals Global Blood Therapeutics Inc.的董事会成员，Bonney先生在贝茨学院获得经济学学士学位。Bonney先生在生物制药行业拥有超过30年的运营、商业和高级管理经验，包括长期担任首席执行官和Cubist董事。
Michael Bonney has served as chair of the board of directors of Autolus Therapeutics plc since April 2024. He has also served as chair of the board of directors of Santa Ana Bio, Inc. since September 2025 and as the chair of the board of directors of Dunad Therapeutics LTD since 2023. He previously served as a director of Alnylam Pharmaceuticals, Inc. from December 2014 to December 2025; as chair of Alnylam from December 2015 to August 2021 and as the company's executive chair from August 2021 to January 2023. Mr. Bonney previously served as the chair of the board of directors of Kaleido Biosciences, Inc., a biotechnology company, from June 2017 until August 2021. Between August 2018 and October 2020, he served as Kaleido's Executive Chair, and served as Kaleido's Chief Executive Officer from June 2017 until August 2018. Mr. Bonney was a Partner at Third Rock Ventures, a healthcare venture firm, from January to July 2016. Mr. Bonney previously served as the Chief Executive Officer and a member of the board of directors of Cubist Pharmaceuticals, Inc., or Cubist, a biopharmaceutical company (now a wholly owned subsidiary of Merck & Co., Inc. ("Merck")), from June 2003 until his retirement in December 2014, coinciding with Cubist's acquisition by Merck for $9.5 billion. From 2016 to 2021, Mr. Bonney owned nd managed a solo advisory practice where he advised first time CEOs. Mr. Bonney previously served as the Chair of the board of directors of Magenta Therapeutics, Inc. and as a director of Bristol Myers Squibb Company, Celgene Corporation (which was acquired by Bristol Myers Squibb), Syros Pharmaceuticals, Inc., X Biotix Therapeutics, Inc., and Sarepta Therapeutics, Inc. Mr. Bonney holds a B.A. in economics from Bates College. - Michael Bonney自2016年10月起担任Magenta Therapeutics, Inc.董事会成员和主席。Bonney先生自2017年6月起担任Kaleido Biosciences，Inc.的行政总裁及主席。2016年1月至7月，Bonney是医疗保健风险投资公司Third Rock Ventures的合伙人。Bonney先生曾在2003年6月至2014年12月期间担任Cubist Pharmaceuticals，Inc.或Cubist的首席执行官和董事会成员，Cubist是一家生物制药公司，现在是默克制药公司的全资子公司。2002年1月至2003年6月担任Cubist总裁兼首席运营官，Bonney先生是医疗保健专用、公开交易基金Tekla Complex的受托人，此外，Bonney先生目前担任Celgene Corporation、Alnylam Pharmaceuticals Inc.和Sarepta Corporation的董事，Bonney先生曾担任NPS Pharmaceuticals Global Blood Therapeutics Inc.的董事会成员，Bonney先生在贝茨学院获得经济学学士学位。Bonney先生在生物制药行业拥有超过30年的运营、商业和高级管理经验，包括长期担任首席执行官和Cubist董事。
- Michael Bonney has served as chair of the board of directors of Autolus Therapeutics plc since April 2024. He has also served as chair of the board of directors of Santa Ana Bio, Inc. since September 2025 and as the chair of the board of directors of Dunad Therapeutics LTD since 2023. He previously served as a director of Alnylam Pharmaceuticals, Inc. from December 2014 to December 2025; as chair of Alnylam from December 2015 to August 2021 and as the company's executive chair from August 2021 to January 2023. Mr. Bonney previously served as the chair of the board of directors of Kaleido Biosciences, Inc., a biotechnology company, from June 2017 until August 2021. Between August 2018 and October 2020, he served as Kaleido's Executive Chair, and served as Kaleido's Chief Executive Officer from June 2017 until August 2018. Mr. Bonney was a Partner at Third Rock Ventures, a healthcare venture firm, from January to July 2016. Mr. Bonney previously served as the Chief Executive Officer and a member of the board of directors of Cubist Pharmaceuticals, Inc., or Cubist, a biopharmaceutical company (now a wholly owned subsidiary of Merck & Co., Inc. ("Merck")), from June 2003 until his retirement in December 2014, coinciding with Cubist's acquisition by Merck for $9.5 billion. From 2016 to 2021, Mr. Bonney owned nd managed a solo advisory practice where he advised first time CEOs. Mr. Bonney previously served as the Chair of the board of directors of Magenta Therapeutics, Inc. and as a director of Bristol Myers Squibb Company, Celgene Corporation (which was acquired by Bristol Myers Squibb), Syros Pharmaceuticals, Inc., X Biotix Therapeutics, Inc., and Sarepta Therapeutics, Inc. Mr. Bonney holds a B.A. in economics from Bates College.
- Tamar Howson
-
Tamar Howson，在Lexicon Pharmaceuticals, Inc.担任企业业务发展执行副总裁。在加入Lexicon Pharmaceuticals, Inc.之前，Howson女士曾在Bristol-Myers Squibb Company担任企业和业务发展高级副总裁，负责对并购、许可和其他外部联盟活动的识别、评估和谈判进行全球监督和管理。此外，Howson女士在SmithKline Beecham工作了近十年，担任高级副总裁兼业务发展总监，并管理该公司的1亿美元风险投资基金SROne。
Tamar Howson has been a member of the Board since October 2019. Ms. Howson has served as an independent director at MEI Pharma, Inc. since September 2019, and Cue Biopharma, Inc. since September 2020. She previously served as an independent director at Organovo Holdings, Inc. from June 2013 until September 2019, Enzymotec until December 2017, ContraVir until October 2018 and Scientus Pharma until December 2019. From January 2009 until December 2011, Ms. Howson worked as a Senior Advisor on the transaction team at JSB Partners, providing business development support to life sciences companies. Before that, she served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals, Inc. Prior to her role at Lexicon Pharmaceuticals, Inc, Ms. Howson was Senior Vice President, Corporate and Business Development at Bristol Myers Squibb Company, responsible for worldwide oversight and management of the identification, evaluation and negotiation of mergers and acquisitions, licensing and other external alliance activities. Additionally, Ms. Howson spent nearly a decade at SmithKline Beecham, where she served as Senior Vice President and Director, Business Development and managed the company' USD 100 million venture capital fund, SR One. - Tamar Howson，在Lexicon Pharmaceuticals, Inc.担任企业业务发展执行副总裁。在加入Lexicon Pharmaceuticals, Inc.之前，Howson女士曾在Bristol-Myers Squibb Company担任企业和业务发展高级副总裁，负责对并购、许可和其他外部联盟活动的识别、评估和谈判进行全球监督和管理。此外，Howson女士在SmithKline Beecham工作了近十年，担任高级副总裁兼业务发展总监，并管理该公司的1亿美元风险投资基金SROne。
- Tamar Howson has been a member of the Board since October 2019. Ms. Howson has served as an independent director at MEI Pharma, Inc. since September 2019, and Cue Biopharma, Inc. since September 2020. She previously served as an independent director at Organovo Holdings, Inc. from June 2013 until September 2019, Enzymotec until December 2017, ContraVir until October 2018 and Scientus Pharma until December 2019. From January 2009 until December 2011, Ms. Howson worked as a Senior Advisor on the transaction team at JSB Partners, providing business development support to life sciences companies. Before that, she served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals, Inc. Prior to her role at Lexicon Pharmaceuticals, Inc, Ms. Howson was Senior Vice President, Corporate and Business Development at Bristol Myers Squibb Company, responsible for worldwide oversight and management of the identification, evaluation and negotiation of mergers and acquisitions, licensing and other external alliance activities. Additionally, Ms. Howson spent nearly a decade at SmithKline Beecham, where she served as Senior Vice President and Director, Business Development and managed the company' USD 100 million venture capital fund, SR One.
- Duane Nash
-
Duane Nash，医学博士，法学博士，自从2013年5月以来任执行副总裁并自2012年3月以来任Immunic, Inc.的首席商务执行官。在2012年3月至2013年5月，他也担任Immunic, Inc.的医学总监。Nash博士在位于就近上的加州大学完成了他的普外科实习。在此期间，他是肝移植小组的医院。Nash 博士也在2002年11月到2008年2月期间在Davis Polk法律事务所作为代理人进行支持产权诉讼和企业问题处理的实践活动。Nash博士从2009年3月到2012年3月他所工作的PacGrowth生命科学公司加入Wedbush PacGrow Life Sciences公司，并在股权研究中成为该公司的副总裁。在2008年4月到2009年3月期间，他成为太平洋成长证券的一名分析师之前，Nash博士曾为Akebia Therapeutics公司董事。这家公司是一家专注于治疗贫血和血管疾病的上市的生物科技公司。自2013年5月任Aerpio Therapeutics Inc公司董事。这家公司是一家进行临床阶段研究的生物制剂公司。其自2012年9月致力于推进对于血管疾病的治疗。Nash博士在威廉姆斯大学获得学士学位，在达特茅斯医学院获得硕士学位，在加州大学伯克利分校或得法学博士，并在牛津大学获得工商管理硕士学位。
Duane Nash has been a member of the Board since January 2019 and served as Chairman of the Board of Directors from April 2019 to December 2025, and as Executive Chairman from April 2020 to December 2025. Dr. Nash joined the Company in 2012, prior to the Exchange Transaction and has held various leadership roles in the Company, including Medical Director, Executive Vice President, Chief Business Officer, President, and Chief Executive Officer, a position he held until April 2019. Prior to joining the Company, Dr. Nash held various positions at Wedbush PacGrow Life Sciences, an investment bank, where he was employed from March 2009 to March 2012, serving most recently as Senior Vice President in Equity Research. Before that, he was a research analyst at Pacific Growth Equities, an investment bank, from April 2008 through March 2009, which was subsequently acquired by Wedbush Securities, Inc. Dr. Nash also practiced as an attorney from November 2002 to February 2008, most recently at the law firm of Davis Polk & Wardell, where he focused on intellectual property litigation and corporate matters. Dr. Nash has served on the board of directors of public and private companies in the pharmaceutical space since 2012. Dr. Nash earned a B.A. in biology from Williams College, an M.D. from Dartmouth Medical School, a J.D. from the University of California, Berkeley, and an M.B.A. from the University of Oxford. Dr. Nash completed his internship in general surgery at the University of California at San Francisco. - Duane Nash，医学博士，法学博士，自从2013年5月以来任执行副总裁并自2012年3月以来任Immunic, Inc.的首席商务执行官。在2012年3月至2013年5月，他也担任Immunic, Inc.的医学总监。Nash博士在位于就近上的加州大学完成了他的普外科实习。在此期间，他是肝移植小组的医院。Nash 博士也在2002年11月到2008年2月期间在Davis Polk法律事务所作为代理人进行支持产权诉讼和企业问题处理的实践活动。Nash博士从2009年3月到2012年3月他所工作的PacGrowth生命科学公司加入Wedbush PacGrow Life Sciences公司，并在股权研究中成为该公司的副总裁。在2008年4月到2009年3月期间，他成为太平洋成长证券的一名分析师之前，Nash博士曾为Akebia Therapeutics公司董事。这家公司是一家专注于治疗贫血和血管疾病的上市的生物科技公司。自2013年5月任Aerpio Therapeutics Inc公司董事。这家公司是一家进行临床阶段研究的生物制剂公司。其自2012年9月致力于推进对于血管疾病的治疗。Nash博士在威廉姆斯大学获得学士学位，在达特茅斯医学院获得硕士学位，在加州大学伯克利分校或得法学博士，并在牛津大学获得工商管理硕士学位。
- Duane Nash has been a member of the Board since January 2019 and served as Chairman of the Board of Directors from April 2019 to December 2025, and as Executive Chairman from April 2020 to December 2025. Dr. Nash joined the Company in 2012, prior to the Exchange Transaction and has held various leadership roles in the Company, including Medical Director, Executive Vice President, Chief Business Officer, President, and Chief Executive Officer, a position he held until April 2019. Prior to joining the Company, Dr. Nash held various positions at Wedbush PacGrow Life Sciences, an investment bank, where he was employed from March 2009 to March 2012, serving most recently as Senior Vice President in Equity Research. Before that, he was a research analyst at Pacific Growth Equities, an investment bank, from April 2008 through March 2009, which was subsequently acquired by Wedbush Securities, Inc. Dr. Nash also practiced as an attorney from November 2002 to February 2008, most recently at the law firm of Davis Polk & Wardell, where he focused on intellectual property litigation and corporate matters. Dr. Nash has served on the board of directors of public and private companies in the pharmaceutical space since 2012. Dr. Nash earned a B.A. in biology from Williams College, an M.D. from Dartmouth Medical School, a J.D. from the University of California, Berkeley, and an M.B.A. from the University of Oxford. Dr. Nash completed his internship in general surgery at the University of California at San Francisco.
高管简历
中英对照 | 中文 | 英文- Michael Panzara
Michael Panzara自2020年5月起担任Wave Life Sciences Ltd.首席医疗官、治疗发现和开发主管。在2018年11月至2020年4月期间，Panzara博士担任Wave Life Sciences Ltd.首席医疗官。在2016年7月至2018年10月期间，Panzara博士担任Wave Life Sciences Ltd.神经病学特许经营主管。在加入Wave Life Sciences Ltd.之前，Panzara博士曾在Sanofi Genzyme和 Genzyme Corporation担任过各种职务，Genzyme Corporation于2011年与赛诺菲合并，从2009年到2016年7月，最近担任多发性硬化症负责人，神经病学和眼科治疗领域的全球发展，在此之前，担任集团副总裁，治疗领域负责人，多发性硬化症和神经病学。在加入Genzyme之前，Panzara博士在Biogen担任过越来越多的职责，包括2006年至2009年担任神经病学副总裁、首席医疗官，以及2001年至2006年在医学研究组担任过各种职务。此外，从1999年到2011年，Panzara博士是哈佛医学院神经病学讲师和马萨诸塞州总医院神经病学助理。他于1994年至1998年在MGH接受神经病学培训，并在布莱根妇女医院完成了免疫学和风湿病学的博士后培训。Panzara博士拥有宾夕法尼亚大学学士学位、斯坦福大学医学院医学学位和哈佛大学公共卫生学院公共卫生硕士学位。
Michael Panzara has served as Wave Life Sciences Ltd. Chief Medical Officer, Head of Therapeutics Discovery and Development since May 2020. During the period of November 2018 through April 2020 Dr. Panzara served as Wave Life Sciences Ltd. Chief Medical Officer. During the period of July 2016 to October 2018 Dr. Panzara served as Wave Life Sciences Ltd. Franchise Lead, Neurology. Prior to joining Wave Life Sciences Ltd., Dr. Panzara served in various roles at Sanofi Genzyme and Genzyme Corporation before its merger with Sanofi in 2011 from 2009 to July 2016 most recently serving as Head of the Multiple Sclerosis, Neurology and Ophthalmology Therapeutic Area for Global Development and prior to that, serving as Group Vice President, Therapeutic Area Head, Multiple Sclerosis and Neurology. Prior to joining Genzyme, Dr. Panzara served in roles of increasing responsibility at Biogen, including Vice President, Chief Medical Officer, Neurology from 2006 to 2009 and in various roles in the Medical Research group from 2001 to 2006. In addition, from 1999 to 2011 Dr. Panzara was an Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at Massachusetts General Hospital (MGH). He trained in neurology at MGH from 1994 to 1998 and completed his post-doctoral training in immunology and rheumatology at Brigham and Women's Hospital. Dr. Panzara holds a bachelor's degree from the University of Pennsylvania, a medical degree from Stanford University School of Medicine, and a master's degree in public health from the Harvard School of Public Health.- Michael Panzara自2020年5月起担任Wave Life Sciences Ltd.首席医疗官、治疗发现和开发主管。在2018年11月至2020年4月期间，Panzara博士担任Wave Life Sciences Ltd.首席医疗官。在2016年7月至2018年10月期间，Panzara博士担任Wave Life Sciences Ltd.神经病学特许经营主管。在加入Wave Life Sciences Ltd.之前，Panzara博士曾在Sanofi Genzyme和 Genzyme Corporation担任过各种职务，Genzyme Corporation于2011年与赛诺菲合并，从2009年到2016年7月，最近担任多发性硬化症负责人，神经病学和眼科治疗领域的全球发展，在此之前，担任集团副总裁，治疗领域负责人，多发性硬化症和神经病学。在加入Genzyme之前，Panzara博士在Biogen担任过越来越多的职责，包括2006年至2009年担任神经病学副总裁、首席医疗官，以及2001年至2006年在医学研究组担任过各种职务。此外，从1999年到2011年，Panzara博士是哈佛医学院神经病学讲师和马萨诸塞州总医院神经病学助理。他于1994年至1998年在MGH接受神经病学培训，并在布莱根妇女医院完成了免疫学和风湿病学的博士后培训。Panzara博士拥有宾夕法尼亚大学学士学位、斯坦福大学医学院医学学位和哈佛大学公共卫生学院公共卫生硕士学位。
- Michael Panzara has served as Wave Life Sciences Ltd. Chief Medical Officer, Head of Therapeutics Discovery and Development since May 2020. During the period of November 2018 through April 2020 Dr. Panzara served as Wave Life Sciences Ltd. Chief Medical Officer. During the period of July 2016 to October 2018 Dr. Panzara served as Wave Life Sciences Ltd. Franchise Lead, Neurology. Prior to joining Wave Life Sciences Ltd., Dr. Panzara served in various roles at Sanofi Genzyme and Genzyme Corporation before its merger with Sanofi in 2011 from 2009 to July 2016 most recently serving as Head of the Multiple Sclerosis, Neurology and Ophthalmology Therapeutic Area for Global Development and prior to that, serving as Group Vice President, Therapeutic Area Head, Multiple Sclerosis and Neurology. Prior to joining Genzyme, Dr. Panzara served in roles of increasing responsibility at Biogen, including Vice President, Chief Medical Officer, Neurology from 2006 to 2009 and in various roles in the Medical Research group from 2001 to 2006. In addition, from 1999 to 2011 Dr. Panzara was an Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at Massachusetts General Hospital (MGH). He trained in neurology at MGH from 1994 to 1998 and completed his post-doctoral training in immunology and rheumatology at Brigham and Women's Hospital. Dr. Panzara holds a bachelor's degree from the University of Pennsylvania, a medical degree from Stanford University School of Medicine, and a master's degree in public health from the Harvard School of Public Health.
- Jason Tardio
Jason Tardio自2019年11月起担任我们的首席商务官。在加入我们之前，Tardio先生于2018年9月至2019年11月担任诺华公司多发性硬化症专营权负责人副总裁，负责开发和管理美国商业计划，品牌损益损益损益，战略发展和进入市场建模的各个方面。在加入诺华之前，Tardio先生于2009年至2018年9月在Biogen担任越来越重要的职务，最近他担任Biogen拉丁美洲南部子公司的总经理。他在生物制药行业20年的商业经验始于Sepracor Inc.和Wyeth Ayerst Laboratories担任多个职位，在那里他担任销售、销售培训和营销职务。Jason持有the College of New Jersey理学学士学位和St.Joseph’s University制药营销工商管理硕士学位。
Jason Tardio joined Immunic in 2024 as Immunic, Inc.'s President and Chief Operating Officer. From July 2021 to July 2024, Mr. Tardio was Chief Operating Officer of Ovid Therapeutics Inc. after joining the firm as Chief Commercial Officer in November 2019. Prior to his role at Ovid Therapeutics, Inc., Mr. Tardio served as Vice President, Head of the Multiple Sclerosis Franchise at Novartis AG from September 2018 to November 2019. Before his employment at Novartis, Mr. Tardio worked for nine years in several capacities at Biogen Inc., where he most recently served as General Manager, Managing Director for the firm's Latin America South affiliate. Mr. Tardio commenced his career in the biopharmaceutical industry at Wyeth Pharmaceuticals Inc. and Sepracor, Inc., respectively, in various sales, sales training, and marketing roles. Mr. Tardio holds a Bachelor of Science from The College of New Jersey and an MBA in Pharmaceutical Marketing from St. Joseph's University.- Jason Tardio自2019年11月起担任我们的首席商务官。在加入我们之前，Tardio先生于2018年9月至2019年11月担任诺华公司多发性硬化症专营权负责人副总裁，负责开发和管理美国商业计划，品牌损益损益损益，战略发展和进入市场建模的各个方面。在加入诺华之前，Tardio先生于2009年至2018年9月在Biogen担任越来越重要的职务，最近他担任Biogen拉丁美洲南部子公司的总经理。他在生物制药行业20年的商业经验始于Sepracor Inc.和Wyeth Ayerst Laboratories担任多个职位，在那里他担任销售、销售培训和营销职务。Jason持有the College of New Jersey理学学士学位和St.Joseph’s University制药营销工商管理硕士学位。
- Jason Tardio joined Immunic in 2024 as Immunic, Inc.'s President and Chief Operating Officer. From July 2021 to July 2024, Mr. Tardio was Chief Operating Officer of Ovid Therapeutics Inc. after joining the firm as Chief Commercial Officer in November 2019. Prior to his role at Ovid Therapeutics, Inc., Mr. Tardio served as Vice President, Head of the Multiple Sclerosis Franchise at Novartis AG from September 2018 to November 2019. Before his employment at Novartis, Mr. Tardio worked for nine years in several capacities at Biogen Inc., where he most recently served as General Manager, Managing Director for the firm's Latin America South affiliate. Mr. Tardio commenced his career in the biopharmaceutical industry at Wyeth Pharmaceuticals Inc. and Sepracor, Inc., respectively, in various sales, sales training, and marketing roles. Mr. Tardio holds a Bachelor of Science from The College of New Jersey and an MBA in Pharmaceutical Marketing from St. Joseph's University.
- Hella Kohlhof
Hella Kohlhof，2017年加入Immunic，担任Immunic, Inc.首席科学官。她在亚琛、哥德堡（瑞典）和慕尼黑学习生物学，并在慕尼黑路德维希·马克西米利亚姆斯大学（德国）获得生物学博士学位。在慕尼黑亥姆霍兹中心临床分子生物学和肿瘤遗传学研究所攻读博士和博士后期间，她研究了受Notch和Epstein Barr病毒介导的信号传导影响的正常和恶性B细胞发育。2008年，她加入4SC AG，担任研究科学家和组长，并建立了转化药理学研究实验室。她参与了4SC来自肿瘤学和免疫学领域的临床前和临床阶段项目，包括IMU-838和IMU-366。从2011年起，Kohlhof博士负责管理和开发4SC的表观遗传临床阶段小分子抑制剂4SC-202。2015年初，作为开发项目总监，她接管了4SC AG完整的开发组合。Kohlhof博士在免疫学和肿瘤学领域拥有强大的科学背景，在药物开发、临床前和转化药理学、临床试验设计和生物标志物开发方面经验丰富。
Hella Kohlhof joined Immunic in 2017 as Immunic, Inc.'s Chief Scientific Officer. She studied biology in Aachen, Gothenborg (Sweden) and Munich and received her Doctorate in Biology from the Ludwig Maximilians University of Munich (Germany). During her Ph.D. and post doctoral position at the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Centre in Munich, she worked on the normal and malignant B cell development influenced by Notch and Epstein Barr Virus mediated signaling. In 2008, she joined 4SC AG as a research scientist and group leader and established the research laboratory for translational pharmacology. She worked on 4SC's preclinical and clinical stage projects from the oncology and immunology field, including IMU 838 and IMU 366. From 2011 onward, Dr. Kohlhof was responsible for the management and development of 4SC's epigenetic clinical stage small molecule inhibitor 4SC 202. In early 2015, as Director of Development Projects, she took over responsibility for the complete development portfolio of 4SC AG. She currently serves as managing director of Immunic Research GmbH, a German subsidiary of the Company, and Constanze Investment GmbH, a German limited liability company, respectively. Dr. Kohlhof has a strong scientific background in the immunology and oncology field and is experienced in drug development, preclinical and translational pharmacology, clinical trial design and bio marker development.- Hella Kohlhof，2017年加入Immunic，担任Immunic, Inc.首席科学官。她在亚琛、哥德堡（瑞典）和慕尼黑学习生物学，并在慕尼黑路德维希·马克西米利亚姆斯大学（德国）获得生物学博士学位。在慕尼黑亥姆霍兹中心临床分子生物学和肿瘤遗传学研究所攻读博士和博士后期间，她研究了受Notch和Epstein Barr病毒介导的信号传导影响的正常和恶性B细胞发育。2008年，她加入4SC AG，担任研究科学家和组长，并建立了转化药理学研究实验室。她参与了4SC来自肿瘤学和免疫学领域的临床前和临床阶段项目，包括IMU-838和IMU-366。从2011年起，Kohlhof博士负责管理和开发4SC的表观遗传临床阶段小分子抑制剂4SC-202。2015年初，作为开发项目总监，她接管了4SC AG完整的开发组合。Kohlhof博士在免疫学和肿瘤学领域拥有强大的科学背景，在药物开发、临床前和转化药理学、临床试验设计和生物标志物开发方面经验丰富。
- Hella Kohlhof joined Immunic in 2017 as Immunic, Inc.'s Chief Scientific Officer. She studied biology in Aachen, Gothenborg (Sweden) and Munich and received her Doctorate in Biology from the Ludwig Maximilians University of Munich (Germany). During her Ph.D. and post doctoral position at the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Centre in Munich, she worked on the normal and malignant B cell development influenced by Notch and Epstein Barr Virus mediated signaling. In 2008, she joined 4SC AG as a research scientist and group leader and established the research laboratory for translational pharmacology. She worked on 4SC's preclinical and clinical stage projects from the oncology and immunology field, including IMU 838 and IMU 366. From 2011 onward, Dr. Kohlhof was responsible for the management and development of 4SC's epigenetic clinical stage small molecule inhibitor 4SC 202. In early 2015, as Director of Development Projects, she took over responsibility for the complete development portfolio of 4SC AG. She currently serves as managing director of Immunic Research GmbH, a German subsidiary of the Company, and Constanze Investment GmbH, a German limited liability company, respectively. Dr. Kohlhof has a strong scientific background in the immunology and oncology field and is experienced in drug development, preclinical and translational pharmacology, clinical trial design and bio marker development.
- Inderpal Singh
Inderpal Singh，于2021年6月加入Immunic，担任Immunic, Inc.总法律顾问。他从Sandoz International GmbH加入，自2018年1月起担任生物制药全球法律主管。在印度获得大学学位后，辛格先生获得了德国美因茨约翰内斯-古腾堡大学公司和商业法专业律师的资格。辛格先生在德国曼海姆大学和法国枫丹白露的INSEAD商学院完成了两个高管MBA课程。在Sandoz任职期间，作为各领导团队的成员，他负责所有法律活动，包括开发、监管和医疗事务，以及生物制药的商业运营、业务发展、联盟管理和市场准入。在此之前，从2015年到2017年，Singh先生曾在默沙东 KGaA担任全球制造和供应全球法律主管以及中东和非洲、独立国家联合体和土耳其的区域法律顾问。2013年至2015年，他在渤健 Idec International GmbH担任法律总监（欧洲）。在其职业生涯的早期，辛格在辉瑞 Deutschland GmbH和辉瑞公司（美国）的法律职位上工作了15年，责任越来越大。
Inderpal Singh joined Immunic in June 2021 as Immunic, Inc.'s General Counsel. He joined from Sandoz International GmbH, where he served as the Global Legal Head of Biopharma since January 2018. After earning his college degree in India, Mr. Singh qualified as an attorney with specialization in Corporate and Commercial Law at Johannes Gutenberg University in Mainz, Germany. Mr. Singh completed two executive MBA programs at the University of Mannheim, Germany and INSEAD Business School in Fontainebleau, France. During his tenure at Sandoz and as a member of various leadership teams, he was responsible for all legal activities, including development, regulatory, and medical matters, as well as commercial operations, business development, alliance management and market access for biopharma. Before that, from 2015 through 2017, Mr. Singh served at Merck KGaA as Global Legal Head of Global Manufacturing and Supply and Regional Counsel of Middle East and Africa, Commonwealth of Independent States and Turkey. From 2013 to 2015, he was Legal Director (Europe) at Biogen Idec International GmbH. Earlier in his career, Mr. Singh spent 15 years in legal positions of increasing responsibility at Pfizer Deutschland GmbH and Pfizer Inc.- Inderpal Singh，于2021年6月加入Immunic，担任Immunic, Inc.总法律顾问。他从Sandoz International GmbH加入，自2018年1月起担任生物制药全球法律主管。在印度获得大学学位后，辛格先生获得了德国美因茨约翰内斯-古腾堡大学公司和商业法专业律师的资格。辛格先生在德国曼海姆大学和法国枫丹白露的INSEAD商学院完成了两个高管MBA课程。在Sandoz任职期间，作为各领导团队的成员，他负责所有法律活动，包括开发、监管和医疗事务，以及生物制药的商业运营、业务发展、联盟管理和市场准入。在此之前，从2015年到2017年，Singh先生曾在默沙东 KGaA担任全球制造和供应全球法律主管以及中东和非洲、独立国家联合体和土耳其的区域法律顾问。2013年至2015年，他在渤健 Idec International GmbH担任法律总监（欧洲）。在其职业生涯的早期，辛格在辉瑞 Deutschland GmbH和辉瑞公司（美国）的法律职位上工作了15年，责任越来越大。
- Inderpal Singh joined Immunic in June 2021 as Immunic, Inc.'s General Counsel. He joined from Sandoz International GmbH, where he served as the Global Legal Head of Biopharma since January 2018. After earning his college degree in India, Mr. Singh qualified as an attorney with specialization in Corporate and Commercial Law at Johannes Gutenberg University in Mainz, Germany. Mr. Singh completed two executive MBA programs at the University of Mannheim, Germany and INSEAD Business School in Fontainebleau, France. During his tenure at Sandoz and as a member of various leadership teams, he was responsible for all legal activities, including development, regulatory, and medical matters, as well as commercial operations, business development, alliance management and market access for biopharma. Before that, from 2015 through 2017, Mr. Singh served at Merck KGaA as Global Legal Head of Global Manufacturing and Supply and Regional Counsel of Middle East and Africa, Commonwealth of Independent States and Turkey. From 2013 to 2015, he was Legal Director (Europe) at Biogen Idec International GmbH. Earlier in his career, Mr. Singh spent 15 years in legal positions of increasing responsibility at Pfizer Deutschland GmbH and Pfizer Inc.
- Patrick Walsh
Patrick Walsh，于2021年10月加入Immunic，担任Immunic, Inc.首席商务官。他从Akebia Therapeutics, Inc.加入，从2015年7月至2021年10月担任业务发展副总裁，完成了一系列战略交易，包括多个合作伙伴关系、许可内、非稀释性融资以及一项合并。沃尔什先生拥有分子、细胞和发育生物学硕士学位和密歇根大学MBA学位，以及科尔比学院生物学和经济学学士学位。Walsh先生之前在AVEO肿瘤学从事企业发展工作，在此期间他致力于业务发展的各个方面。在其职业生涯的早期，Walsh先生曾是Capgemini SE的生命科学公司顾问，并曾是Leerink Partners（现为SVB Securities）的医疗保健投资银行团队成员。
Patrick Walsh joined Immunic in October 2021 as Immunic, Inc.'s Chief Business Officer. He joined from Akebia Therapeutics, Inc., where he served as Vice President of Business Development from July 2015 until October 2021 and completed an array of strategic transactions, including multiple partnerships, in licenses, non dilutive financings, and a merger. Mr. Walsh holds both an M.S. in molecular, cellular and developmental biology and an MBA from the University of Michigan and a B.A. in biology and economics from Colby College. Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development. Earlier in his career, Mr. Walsh was a consultant to life science companies with Capgemini SE and was on the healthcare investment banking team at Leerink Partners.- Patrick Walsh，于2021年10月加入Immunic，担任Immunic, Inc.首席商务官。他从Akebia Therapeutics, Inc.加入，从2015年7月至2021年10月担任业务发展副总裁，完成了一系列战略交易，包括多个合作伙伴关系、许可内、非稀释性融资以及一项合并。沃尔什先生拥有分子、细胞和发育生物学硕士学位和密歇根大学MBA学位，以及科尔比学院生物学和经济学学士学位。Walsh先生之前在AVEO肿瘤学从事企业发展工作，在此期间他致力于业务发展的各个方面。在其职业生涯的早期，Walsh先生曾是Capgemini SE的生命科学公司顾问，并曾是Leerink Partners（现为SVB Securities）的医疗保健投资银行团队成员。
- Patrick Walsh joined Immunic in October 2021 as Immunic, Inc.'s Chief Business Officer. He joined from Akebia Therapeutics, Inc., where he served as Vice President of Business Development from July 2015 until October 2021 and completed an array of strategic transactions, including multiple partnerships, in licenses, non dilutive financings, and a merger. Mr. Walsh holds both an M.S. in molecular, cellular and developmental biology and an MBA from the University of Michigan and a B.A. in biology and economics from Colby College. Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development. Earlier in his career, Mr. Walsh was a consultant to life science companies with Capgemini SE and was on the healthcare investment banking team at Leerink Partners.
- Glenn Whaley
Glenn Whaley，2019年12月加入Immunic，担任首席会计官、财务总监。2020年4月晋升为财务副总裁、首席财务会计官。2022年3月晋升为首席财务官职务。Whaley先生在会计和财务方面拥有30多年的经验。在加入Immunic, Inc.之前，Whaley先生于2015年3月至2019年5月担任品牌和仿制药公司Pernix Therapeutics的财务副总裁。其职责包括2018年11月至2019年5月担任首席财务和会计官，2017年12月至2018年11月担任首席会计官和财务总监，2015年3月至2017年11月担任财务规划和分析副总裁。沃利先生在2011年5月至2015年3月期间担任全球制药公司Alvogen，Inc的财务副总裁。他的职责包括2013年8月至2015年3月的美国业务财务副总裁和2011年5月至2013年8月的全球公司财务总监。在加入Alvogen之前，Whaley先生曾于2007年1月至2011年5月担任ImClone Systems的公司财务总监，该公司是一家致力于开发肿瘤领域生物药物的生物制药公司，并于2005年1月至2006年12月担任财务报告高级总监。在加入ImClone Systems之前，Whaley先生曾在公共会计、制药和电信行业担任越来越多的财务职务。Whaley先生拥有罗格斯大学商学院理学学士学位，是新泽西州注册会计师协会和美国注册会计师协会的成员。
Glenn Whaley joined Immunic as Principal Accounting Officer and Controller in December 2019. In April 2020, he was promoted to the position of Vice President Finance, Principal Financial and Accounting Officer. In March 2022, he was promoted to the position of Chief Financial Officer. Mr. Whaley has more than 30 years of experience in accounting and finance roles. Prior to joining Immunic, Inc., Mr. Whaley was Vice President of Finance at Pernix Therapeutics, a branded and generics pharmaceutical company, from March 2015 until May 2019. His responsibilities included Principal Financial and Accounting Officer, from November 2018 until May 2019, Principal Accounting Officer and Controller from December 2017 until November 2018 and Vice President of Financial Planning and Analysis from March 2015 until November 2017. Mr. Whaley was Vice President of Finance for Alvogen, Inc., a global pharmaceutical company, from May 2011 until March 2015. His responsibilities included Vice President Finance of U.S. Operations from August 2013 to March 2015 and Global Corporate Controller from May 2011 to August 2013. Prior to Alvogen, Mr. Whaley served as Corporate Controller for ImClone Systems, a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology, from January 2007 to May 2011 and Senior Director of Financial Reporting from January 2005 to December 2006. Prior to ImClone Systems, Mr. Whaley served in financial roles at increasing levels of responsibility in public accounting and the pharmaceutical and telecommunications industries. Mr. Whaley holds a Bachelor of Science degree from Rutgers University Business School and is a Member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.- Glenn Whaley，2019年12月加入Immunic，担任首席会计官、财务总监。2020年4月晋升为财务副总裁、首席财务会计官。2022年3月晋升为首席财务官职务。Whaley先生在会计和财务方面拥有30多年的经验。在加入Immunic, Inc.之前，Whaley先生于2015年3月至2019年5月担任品牌和仿制药公司Pernix Therapeutics的财务副总裁。其职责包括2018年11月至2019年5月担任首席财务和会计官，2017年12月至2018年11月担任首席会计官和财务总监，2015年3月至2017年11月担任财务规划和分析副总裁。沃利先生在2011年5月至2015年3月期间担任全球制药公司Alvogen，Inc的财务副总裁。他的职责包括2013年8月至2015年3月的美国业务财务副总裁和2011年5月至2013年8月的全球公司财务总监。在加入Alvogen之前，Whaley先生曾于2007年1月至2011年5月担任ImClone Systems的公司财务总监，该公司是一家致力于开发肿瘤领域生物药物的生物制药公司，并于2005年1月至2006年12月担任财务报告高级总监。在加入ImClone Systems之前，Whaley先生曾在公共会计、制药和电信行业担任越来越多的财务职务。Whaley先生拥有罗格斯大学商学院理学学士学位，是新泽西州注册会计师协会和美国注册会计师协会的成员。
- Glenn Whaley joined Immunic as Principal Accounting Officer and Controller in December 2019. In April 2020, he was promoted to the position of Vice President Finance, Principal Financial and Accounting Officer. In March 2022, he was promoted to the position of Chief Financial Officer. Mr. Whaley has more than 30 years of experience in accounting and finance roles. Prior to joining Immunic, Inc., Mr. Whaley was Vice President of Finance at Pernix Therapeutics, a branded and generics pharmaceutical company, from March 2015 until May 2019. His responsibilities included Principal Financial and Accounting Officer, from November 2018 until May 2019, Principal Accounting Officer and Controller from December 2017 until November 2018 and Vice President of Financial Planning and Analysis from March 2015 until November 2017. Mr. Whaley was Vice President of Finance for Alvogen, Inc., a global pharmaceutical company, from May 2011 until March 2015. His responsibilities included Vice President Finance of U.S. Operations from August 2013 to March 2015 and Global Corporate Controller from May 2011 to August 2013. Prior to Alvogen, Mr. Whaley served as Corporate Controller for ImClone Systems, a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology, from January 2007 to May 2011 and Senior Director of Financial Reporting from January 2005 to December 2006. Prior to ImClone Systems, Mr. Whaley served in financial roles at increasing levels of responsibility in public accounting and the pharmaceutical and telecommunications industries. Mr. Whaley holds a Bachelor of Science degree from Rutgers University Business School and is a Member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.
- Werner Gladdines
Werner Gladdines在不同商业和临床阶段的生物技术公司（包括AIMM Therapeutics B.V.、Rainier Therapeutics，Inc.、拜玛林制药股份有限公司、Prosensa Therapeutics B.V.、to-BBB technologies B.V.和Genzyme Corp.）建立和领导全球药物开发、临床运营和临床科学团队方面拥有20多年的经验，Gladdines先生还执行了战略发展和运营计划，为患者提供了及时和有意义的疗法，并积极促进了三种医药产品的注册和20多项国际1至4期临床研究的成功交付。Gladdines先生在荷兰莱顿大学获得生物制药科学硕士学位，在那里他专注于开发描述神经活性类固醇的浓度-效应关系的数学模型。
Werner Gladdines joined Immunic in January 2021 as Head of the IMU 838 Program, and since that time held positions of increasing responsibility with the Company, and was appointed Vice President, Program Management & Clinical Development Operations in February 2023. In July 2024, he was appointed Chief Development Officer. Mr. Gladdines has more than 20 years of experience in building and leading global drug development, clinical operations and clinical sciences teams in oncology, neurology and rare disease therapeutic areas across different commercial and clinical stage biotechnology companies, including AIMM Therapeutics B.V., Rainier Therapeutics, Inc., Biomarin Pharmaceutical Inc., Prosensa Therapeutics B.V., to BBB technologies B.V. and Genzyme Corp. During his career, Mr. Gladdines has also executed strategic development and operational plans that have delivered timely and meaningful therapies for patients and has actively contributed to the registration of three medicinal products and the successful delivery of over 20 international phase 1 to phase 4 clinical studies. Mr. Gladdines earned a master's degree in bio pharmaceutical sciences from the University of Leiden, The Netherlands, where he focused on developing mathematical models describing concentration effect relationships of neuroactive steroids.- Werner Gladdines在不同商业和临床阶段的生物技术公司（包括AIMM Therapeutics B.V.、Rainier Therapeutics，Inc.、拜玛林制药股份有限公司、Prosensa Therapeutics B.V.、to-BBB technologies B.V.和Genzyme Corp.）建立和领导全球药物开发、临床运营和临床科学团队方面拥有20多年的经验，Gladdines先生还执行了战略发展和运营计划，为患者提供了及时和有意义的疗法，并积极促进了三种医药产品的注册和20多项国际1至4期临床研究的成功交付。Gladdines先生在荷兰莱顿大学获得生物制药科学硕士学位，在那里他专注于开发描述神经活性类固醇的浓度-效应关系的数学模型。
- Werner Gladdines joined Immunic in January 2021 as Head of the IMU 838 Program, and since that time held positions of increasing responsibility with the Company, and was appointed Vice President, Program Management & Clinical Development Operations in February 2023. In July 2024, he was appointed Chief Development Officer. Mr. Gladdines has more than 20 years of experience in building and leading global drug development, clinical operations and clinical sciences teams in oncology, neurology and rare disease therapeutic areas across different commercial and clinical stage biotechnology companies, including AIMM Therapeutics B.V., Rainier Therapeutics, Inc., Biomarin Pharmaceutical Inc., Prosensa Therapeutics B.V., to BBB technologies B.V. and Genzyme Corp. During his career, Mr. Gladdines has also executed strategic development and operational plans that have delivered timely and meaningful therapies for patients and has actively contributed to the registration of three medicinal products and the successful delivery of over 20 international phase 1 to phase 4 clinical studies. Mr. Gladdines earned a master's degree in bio pharmaceutical sciences from the University of Leiden, The Netherlands, where he focused on developing mathematical models describing concentration effect relationships of neuroactive steroids.
- Erik Lundgren
Erik Lundgren，于2024年5月至2026年5月期间在罗氏集团成员基因泰克担任商业投资组合组织高级副总裁，领导并监督该公司投资组合所有治疗领域的商业战略。在担任该职务之前，Lundgren先生于2021年4月至2024年5月期间担任罗氏集团总经理。Lundgren先生于2018年1月至2021年5月在罗氏担任亨廷顿病生命周期领导者。在此之前，Lundgren先生曾于2007年5月至2017年12月在Genentech担任越来越多的职责，包括担任高级营销总监，支持Ocrevus的发布和商业化（ocrelizumab）。Lundgren先生的职业生涯始于咨询行业。Lundgren先生在杜克大学获得公共政策文学学士学位，在哈佛商学院获得工商管理硕士学位。
Erik Lundgren served as Senior Vice President, Commercial Portfolio Organization at Genentech, Inc., a member of the Roche Group, from May 2024 to May 2026, where he led and oversaw the commercial strategy across all therapeutic areas of the company's portfolio. Prior to that role, Mr. Lundgren was the General Manager of Roche s.r.o. from April 2021 to May 2024. Mr. Lundgren was the Lifecycle Leader for Huntington's disease at Roche from January 2018 to May 2021. Prior to that, Mr. Lundgren served in roles of increasing responsibility at Genentech from May 2007 to December 2017, including serving as Senior Marketing Director supporting the launch and commercialization of Ocrevus[](ocrelizumab). Mr. Lundgren began his career in the consulting industry.- Erik Lundgren，于2024年5月至2026年5月期间在罗氏集团成员基因泰克担任商业投资组合组织高级副总裁，领导并监督该公司投资组合所有治疗领域的商业战略。在担任该职务之前，Lundgren先生于2021年4月至2024年5月期间担任罗氏集团总经理。Lundgren先生于2018年1月至2021年5月在罗氏担任亨廷顿病生命周期领导者。在此之前，Lundgren先生曾于2007年5月至2017年12月在Genentech担任越来越多的职责，包括担任高级营销总监，支持Ocrevus的发布和商业化（ocrelizumab）。Lundgren先生的职业生涯始于咨询行业。Lundgren先生在杜克大学获得公共政策文学学士学位，在哈佛商学院获得工商管理硕士学位。
- Erik Lundgren served as Senior Vice President, Commercial Portfolio Organization at Genentech, Inc., a member of the Roche Group, from May 2024 to May 2026, where he led and oversaw the commercial strategy across all therapeutic areas of the company's portfolio. Prior to that role, Mr. Lundgren was the General Manager of Roche s.r.o. from April 2021 to May 2024. Mr. Lundgren was the Lifecycle Leader for Huntington's disease at Roche from January 2018 to May 2021. Prior to that, Mr. Lundgren served in roles of increasing responsibility at Genentech from May 2007 to December 2017, including serving as Senior Marketing Director supporting the launch and commercialization of Ocrevus[](ocrelizumab). Mr. Lundgren began his career in the consulting industry.